Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Keeping Track: Trulance Is First Novel Drug Of 2017; Vantrela ER Is Year's Second Abuse-Deterrent Opioid

Executive Summary

The latest drug development news and highlights from our FDA Performance Tracker.

Advertisement

Related Content

EpiPen Rival Heads Back To Market After kaléo Retools With ‘100% Automated’ Production
Egalet's Bid For Arymo ER Intranasal Abuse-Deterrence Claim Blocked By MorphaBond Exclusivity
Keeping Track: US FDA Approves Spinraza And Rubraca, Delays Ocrevus; Plus Submissions Galore
AbbVie Makes Further Inroads In Oncology As Humira Loss Looms
Lilly's Olumiant To Be EU's First RA JAK Inhibitor, But Pricing Is Key
Advantage For Synergy’s Plecanatide Over Rival Linzess Holds Up In IBS-C
Keeping Track: Submissions For Dupilumab, Nusinersen; AbbVie Finds Breakthrough Space In Hep C
With Baricitinib, Lilly Hopes To Succeed Where Pfizer Has Struggled
Synergy Flaunts Constipation Data From Linzess Challenger
Keeping Track: For Invega Sustenna, PRIDE Comes Before The "Complete Response"

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

PS119883

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel